Application of adipose-derived mesenchymal stem cells/sustained-release rifampin-loaded microsphere complex in an animal model of spinal tuberculosis

doi:10.3969/j.issn.2095-4344.2017.26.016

Abstract

Abstract:

BACKGROUND: To prepare a novel biological material that can be implanted into the lesion of bone tuberculosis, keep sustained release of anti-tuberculosis drugs around bone tuberculosis tissues for a long time, and enhance the effect on bone repair has become a hot spot for clinical studies on bone tuberculosis.

OBJECTIVE: To prepare the adipose-derived mesenchymal stem cells (ADMSCs)/sustained-release rifampin-loaded microsphere complex, and to preliminarily study its effects in a rabbit model of spinal tuberculosis.

METHODS: Rifampin-chitosan-calcium alginate sustained-release microspheres were synthesized, and co-cultured with ADMSCs to prepare an anti-tuberculosis composite for bone tissue engineering. Forty New Zealand rabbits were used to make lumbar L₆ tuberculosis models. Thereafter, rat models were randomly divided into four groups and given rifampin by gavage in rifampin group, ADMSCs by paravertebral injection+rifampin by gavage in stem cell group, rifampin by gavage+implantation of the anti-tuberculosis composite material in experimental group, and no treatment in control group. The duration time of rifampin administration was 8 weeks. The anti-tuberculosis effect of the composite material was evaluated by X-ray and CT scanning observation.

RESULTS AND CONCLUSION: In the control group, obvious damage to lumbar vertebrae L₅ and L₆ was apparent; inflammatory granulation tissues formed; and the intervertebral space was narrowed. In addition, two rabbits in the control group showed obvious kyphotic deformity and five showed pasoas major swelling with low-density dark region in the psoas muscle. In the rifampin group, there were five rabbits with moderate damage of the lumbar vertebrae L₅ and L₆, and two rabbits with pasoas major swelling. In the stem cell group, there were two rabbits with moderate damage of the lumbar vertebrae L₅ and L₆, three rabbits with mild damage of the upper part of the lumbar vertebra L₆, and three rabbits with pasoas major swelling. In the experimental group, only four rabbits suffered from mild damage of the upper part of the lumbar vertebra L₆ but with no changes in the intervertebral space between the L₅ and L₆, and without pasoas major swelling. These results indicate that the composite material of ADMSCs combined with sustained-release rifampin-loaded microspheres can inhibit mycobacterial growth effectively, and reduce vertebral bone destruction, thereby giving some therapeutic actions for the animal models with spinal tuberculosis.

中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

Key words: Delayed-Action Preparations, Stem Cells, Rifampin, Tuberculosis, Spinal

CLC Number:

R318

Huang Zheng-hui, Liu Wei, Wang Jing-li. Application of adipose-derived mesenchymal stem cells/sustained-release rifampin-loaded microsphere complex in an animal model of spinal tuberculosis[J]. Chinese Journal of Tissue Engineering Research, 2017, 21(26): 4192-4198.

Figures/Tables 5

References

[1]陶亢,张峥,呼西旦,等.兔脊柱结核模型建立的实验研究[J].新疆医科大学学报,2015, 38(8):937-940.

[2]Kumar K.Spinal tuberculosis, natural history of disease, classifications and principles of management with historical perspective.Eur J Orthop Surg Traumatol.2016; 26(6): 551-558.

[3]费正奇,胡蕴玉.抗骨结核缓释药物: 载体材料的选择[J].中国组织工程研究,2015,19(21): 3387-3391.

[4]Kaur M,Garg T,Narang RK.A review of emerging trends in the treatment of tuberculosis.Artif Cells Nanomed Biotechnol. 2016;44(2):478-484.

[5]赵宇,杨民.脂肪间充质干细胞向成骨细胞分化的研究进展[J].局解手术学杂志,2016, 25(9):694-696.

[6]Wang N,Wang F,Gao Y,et al.Curcumin protects human adipose-derived mesenchymal stem cells against oxidative stress-induced inhibition of osteogenesis.J Pharmacol Sci. 2016; 132(3):192-200.

[7]王爱欣.利福平与利福喷汀抗结核治疗效果对比分析[J].国外医药:抗生素分册,2015, 36(4):179-180.

[8]张峥,姜涛,李海建,等.利福喷丁聚乳酸缓释微球对兔脊柱结核局部治疗作用的药效评价[J].新疆医科大学学报, 2015,38(8): 945-948.

[9]周永泰,韩鹏,廖从辉.脊柱结核手术治疗结合术后化疗的临床效果[J].临床骨科杂志,2016, 19(6):698.

[10]蒋之,屈满英,万轲.耐药脊柱结核的临床分析及疗效研究[J].中国现代医学杂志,2016, 26(11):132-136.

[11]占道禄,林明侠,沈宁江,等.脊柱结核微创治疗研究的现状与进展[J].海南医学,2014, 25(2):230-232.

[12]肖骁,王锡阳,罗承科.脊柱结核的外科治疗进展[J].现代实用医学, 2016,28(6): 703-704.

[13]施建党,杨宗强.局部药物缓释材料在脊柱结核骨缺损修复中的应用[J].中国组织工程研究,2015,19(53):8643-8643.

[14]梁求真,折胜利,宋兴华,等.体外构建抗结核性骨组织工程复合体的实验研究[J].中国矫形外科杂志,2014,22(19):1789-1796.

[15]孙效虎,袁景,张宇,等.功能型骨组织工程支架修复结核性骨缺损[J].中国组织工程研究,2016,20(30):4539-4546.

[16]郭欢,邵安良,程祥,等.生物人工肝用海藻酸钠/壳聚糖微囊的安全性和生物功能评价[J]. 药物分析杂志,2016,36(1):36-45.

[17]李凤红,张欣蕊,相丽英,等.海藻酸钠/壳聚糖载药纳米微球的研究进展[J].化工新型材料, 2016,44(1):31-33.

[18]汪程,汪令伟,史晓宇,等.海藻酸钠壳聚糖微球作为药物载体的研究进展[J].现代生物医学进展,2014,14(16): 3174-3176.

[19]魏红领,刘韶瑞,陆宁.雷帕霉素-壳聚糖-海藻酸钙缓释微球抑制青光眼滤过术区瘢痕增殖的实验研究[J].眼科新进展, 2016, 36(2):110-115.

[20]赛佳明,陈东亮,江晓路. BMP2-海藻酸钠-壳聚糖微球对骨折愈合影响[J].青岛大学医学院学报,2016,52(1):68-70.

[21]李德超,何梦乔,李慕勤,等.纯钛微弧氧化-壳聚糖-海藻酸钠涂层的细胞相容性研究[J].口腔医学研究,2016,32(6):559-563.

[22]刘苗,赵雯,李德超,等.纯钛超声微弧氧化-壳聚糖/海藻酸钠自组装种植体的动物实验研究[J].口腔医学研究, 2016,32(7): 667-671.

[23]岳学锋,张俊,施建党,等.复合 HRZ/PLGA 缓释抗结核药涂层材料在兔脊柱结核病灶释药研究[J].中国脊柱脊髓杂志, 2016, 26(6):537-544.

[24]Huang D,Li D,Wang T,et al.Isoniazid conjugated poly (lactide-co-glycolide): Long-term controlled drug release and tissue regeneration for bone tuberculosis therapy. Biomaterials.2015;52:417-425.

[25]Shaarani S,Hamid SS,Mohd Kaus NH.The Influence of Pluronic F68 and F127 Nanocarrier on Physicochemical Properties, <i>In vitro</i> Release, and Antiproliferative Activity of Thymoquinone Drug.Pharmacognosy Res. 2017; 9(1):12-20.

[26]Wang L,Yang Q,Chen Y,et al.A reformative shear precipitation procedure for the fabrication of vancomycin-loaded poly(lactide-co-glycolide) microspheres.J Biomater Appl.2017; 31(7):995-1009.

[27]Abulateefeh SR,Alkawareek MY,Abdullah FR,et al. Preparation of Aqueous Core-Poly(d,l-Lactide-co-Glycolide) Shell Microcapsules With Mononuclear Cores by Internal Phase Separation: Optimization of Formulation Parameters.J Pharm Sci.2017.pii: S0022-3549(16)41953-2.doi: 10.1016/j.xphs.2016.12.027. [Epub ahead of print]

[28]Chen X,Chen J,Li B,et al.PLGA-PEG-PLGA triblock copolymeric micelles as oral drug delivery system: In vitro drug release and in vivo pharmacokinetics assessment.J Colloid Interface Sci.2017;490:542-552.

[29]Ignjatovi? NL,Penov-Gaši KM,Wu VM,et al.Selective anticancer activity of hydroxyapatite/chitosan-poly(d,l)- lactide-co-glycolide particles loaded with an androstane-based cancer inhibitor.Colloids Surf B Biointerfaces.2016;148:629-639.

[30]Alibolandi M,Abnous K,Hadizadeh F,et al.Dextran-poly lactide-co-glycolide polymersomes decorated with folate-antennae for targeted delivery of docetaxel to breast adenocarcinima in vitro and in vivo.J Control Release.2016; 241:45-56.

[31]Reinbold J,Hierlemann T,Hinkel H,et al.Development and in vitro characterization of poly(lactide-<i>co</i>-glycolide) microspheres loaded with an antibacterial natural drug for the treatment of long-term bacterial infections.Drug Des Devel Ther. 2016;10:2823-2832.

[32]Rumian ?,Tiainen H,Cibor U,et al.Ceramic scaffolds enriched with gentamicin loaded poly(lactide-co-glycolide) microparticles for prevention and treatment of bone tissue infections.Mater Sci Eng C Mater Biol Appl.2016;69:856-864.

[33]Chu Z,Li X,Li Y,et al.Effects of different fluid shear stress patterns on the in vitro degradation of poly(lactide-co-glycolide) acid membranes.J Biomed Mater Res A.2017;105(1):23-30.

[34]Bohr A,Water JJ,Wang Y,et al.Potential of surface-eroding poly(ethylene carbonate) for drug delivery to macrophages.Int J Pharm.2016;511(2):814-820.

[35]Costa MP,Feitosa AC,Oliveira FC,et al.Controlled Release of Nor-β-lapachone by PLGA Microparticles: A Strategy for Improving Cytotoxicity against Prostate Cancer Cells.Molecules.2016;21(7).pii:E873.doi:10.3390/molecules21070873.

[36]Sun D,Xue A,Zhang B,et al.Enhanced oral bioavailability of acetylpuerarin by poly(lactide-co-glycolide) nanoparticles optimized using uniform design combined with response surface methodology.Drug Des Devel Ther. 2016;10: 2029-2039.

[37]Kavas A,Keskin D,Altunba? K,et al.Raloxifene-/ raloxifene-poly(ethylene glycol) conjugate-loaded microspheres: A novel strategy for drug delivery to bone forming cells.Int J Pharm. 2016;510(1):168-183.

[38]席焱海,赵鹏,邓翠君,等.阶梯缓释抗结核纳米人工骨复合体成骨性能的实验研究[J].生物骨科材料与临床研究, 2014,11(3): 10-13,19.

[39]Kim Y,Lee SH,Kang B,et al.Comparison of Osteogenesis between Adipose-Derived Mesenchymal Stem Cells and Their Sheets on Poly--Caprolactone/-Tricalcium Phosphate Composite Scaffolds in Canine Bone Defects.Stem Cells Int.2016;2016:8414715.

[40]王瀚,马敏,尹峰.脂肪干细胞治疗骨关节炎的研究进展及应用前景[J].中华关节外科杂志(电子版),2016,10(3):337-340.

[41]美丽,刘少英,刘福艳,等.脂肪组织来源干细胞治疗骨关节炎研究进展[J].国际骨科学杂志,2016,37(2):102-105.

[42]孙玺淳,巩凡,牛东生,等.脂肪间充质干细胞结合透明质酸钠对兔骨性关节炎治疗的实验研究[J].中国矫形外科杂志, 2013, 21(19):1991-1997.